Biosimilar Labeling Dissected: Sandoz’s Zarxio Uses Amgen’s Neupogen Text
Executive Summary
FDA took same approach with biosimilar labeling that it takes with generic drug and 505(b)(2) products, Office of New Drugs Director Jenkins says. Labeling for filgrastim-sndz contains clinical data from Neupogen label, but not Sandoz’ clinical studies.
You may also be interested in...
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Drug Review Profile of TNF-inhibitor etanercept-szzs examines how US FDA navigated its way around ‘inaccurate’ pediatric psoriasis labeling for the reference product, Amgen’s Enbrel, to reflect current state of the knowledge on the biosimilar’s labeling, albeit only temporarily.
Sandoz’s Erelzi: Biosimilar Pediatric Labeling Strayed From Enbrel
Drug Review Profile of TNF-inhibitor etanercept-szzs examines how US FDA navigated its way around ‘inaccurate’ pediatric psoriasis labeling for the reference product, Amgen’s Enbrel, to reflect current state of the knowledge on the biosimilar’s labeling, albeit only temporarily.
US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.